NLRP3 and urogenital neoplasm: In addition, a growing body of evidence suggested that dihydroberberine, the derivative of BBR, could inhibit NLRP3 inflammasome activation to mitigate kidney inflammation and dysfunction (Xu et al. 2021a; Lin et al. 2021).